导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 1.81% | 1965/4773 |
| 近一周 | -1.60% | 1360/5458 |
| 近一月 | -2.18% | 1415/5421 |
| 近一季 | -4.85% | 2514/5205 |
| 近半年 | 1.06% | 1154/4920 |
| 近一年 | 4.92% | 1763/4361 |
| 近两年 | 57.21% | 1305/2954 |
| 近三年 | 34.45% | 896/2253 |
| 成立以来 | 82.04% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.42% 3194/4961 |
17.24% 1481/5312 |
- - |
- - |
| 2025 | 24.20% 1801/4813 |
-0.04% 2035/3635 |
2.96% 1235/4076 |
19.06% 2196/4524 |
1.37% 1401/4813 |
| 2024 | 13.80% 1105/3463 |
1.99% 836/2808 |
-1.25% 1003/3014 |
15.11% 1809/3129 |
-1.84% 1854/3463 |
| 2023 | -9.01% 1088/2656 |
3.55% 1169/2280 |
-4.55% 1199/2385 |
-2.15% 627/2515 |
-5.92% 1559/2655 |
| 2022 | -17.30% 572/2207 |
-12.91% 667/1919 |
6.80% 603/2016 |
-11.10% 492/2113 |
0.02% 1548/2208 |
| 2021 | 13.13% 366/1822 |
-0.11% 330/1255 |
14.20% 264/1330 |
-1.87% 547/1466 |
1.06% 1014/1822 |
| 2020 | 46.72% 206/1250 |
-6.17% 464/1028 |
19.51% 297/1067 |
16.98% 123/1164 |
11.85% 515/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 建信MSCI中国A股指数增强A VS. 长安沪深300非周期A(740101) |